Photo of Arnold S. Freedman,  MD

Arnold S. Freedman, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3441
Fax: (617) 632-5235


arnold_freedman@dfci.harvard.edu

Arnold S. Freedman, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

My laboratory focus is on how the malignant microenvironment affects the growth and survival of B cell leukemias and lymphomas. This involves studies of supportive cells and the cell-cell contact and soluble factors which they provide for malignant B cells. In the area of clinical research, I have focused on the role of high dose therapy in indolent lymphomas and strategies to improve this treatment. This includes improvements in purging tumor cells from the normal hematopoietic stem cells and post-transplant therapies using immunotherapeutic approaches with cytokines and monoclonal antibodies.

Publications

Powered by Harvard Catalyst
  • Jacobson CA, Freedman AS. Rethinking Prognosis and Therapy for Follicular Lymphoma. J Clin Oncol 2015. PubMed
  • Jacobson CA, Freedman AS. Is Observation Dead in Follicular Lymphoma? Still Appropriate. J Natl Compr Canc Netw 2015; 13:367-370. PubMed
  • Ganapathi KA, Pittaluga S, Odejide OO, Freedman AS, Jaffe ES. Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica 2014; 99:1421-32. PubMed
  • Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma 2014. PubMed
  • Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol 2014; 32:1797-803. PubMed
  • Fanale M, Assouline S, Kuruvilla J, Solal-CĂ©ligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. British Journal of Haematology 2014; 164:258-65. PubMed
  • Rendleman J, Antipin Y, Reva B, Adaniel C, Przybylo JA, Dutra-Clarke A, Hansen N, Heguy A, Huberman K, Borsu L, Paltiel O, Ben-Yehuda D, Brown JR, Freedman AS, Sander C, Zelenetz A, Klein RJ, Shao Y, Lacher M, Vijai J, Offit K, Kirchhoff T. Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma. PLoS ONE 2014; 9:e101685. PubMed
  • Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. British Journal of Haematology 2013; 163:123-6. PubMed
  • Jacobson CA, Freedman AS. One size does not fit all in follicular lymphoma. J Clin Oncol 2013; 31:3307-8. PubMed
  • Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma. Haematologica 2013. PubMed
  • Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet 2013; 381:1163-5. PubMed
  • Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. British Journal of Haematology 2013; 160:608-17. PubMed
  • Barnes J, Jacobsen E, Feng Y, Freedman A, Hochberg E, Lacasce A, Armand P, Joyce R, Sohani A, Rodig S, Neuberg D, Fisher D, Abramson J. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2012. PubMed
  • Giardino AA, Shinagare AB, Shinagare SA, Dewar R, Weckstein D, Mauch P, Ramaiya NH, Freedman AS. Primary bone lymphoma involving bilateral tibia. Am J Hematol 2012; 87:924-5. PubMed
  • Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes SM, Thompson C, Macconaill L, Wu CJ, Van de Peer Y, Correll M, Regev A, Neuberg D, Freedman AS. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18:3791-802. PubMed
  • Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD, For The Cancer Leukemia Group B And Eastern Cooperative Oncology Group . A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma 2011; 52:587-96. PubMed
  • Sweetenham JW, Freedman AS. Early initial therapy of advanced follicular lymphoma: the need for vigilance. Leuk Lymphoma 2011; 52:355-7. PubMed
  • Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. British Journal of Haematology 2010; 151:336-45. PubMed
  • Yoon SO, Zhang X, Freedman AS, Zahrieh D, Lossos IS, Li L, Choi YS. Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. Am J Pathol 2010; 177:377-86. PubMed
  • Pozdnyakova O, Spieler PJ, Abraham J, Freedman AS, Kutok JL. Epstein-barr virus-associated diffuse large B-cell lymphoma in an immunocompetent woman. J Clin Oncol 2010; 28:e75-8. PubMed
  • Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology 2009; 146:282-91. PubMed
  • Brown JR, Freedman AS. ASCT in follicular lymphoma. Nat Rev Clin Oncol 2009; 6:380-2. PubMed
  • Brown JR,Friedberg JW,Feng Y,Scofield S,Phillips K,Dal Cin P,Joyce R,Takvorian RW,Fisher DC,Fisher RI,Liesveld J,Marquis D,Neuberg D,Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. British Journal of Haematology 2009; 145:741-8. PubMed
  • Armand P,Gannamaneni S,Kim HT,Cutler CS,Ho VT,Koreth J,Alyea EP,LaCasce AS,Jacobsen ED,Fisher DC,Brown JR,Canellos GP,Freedman AS,Soiffer RJ,Antin JH. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26:5767-74. PubMed
  • Luthy SK,Ng AK,Silver B,Degnan KO,Fisher DC,Freedman AS,Mauch PM. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol 2008; 19:2043-7. PubMed
  • Brown JR,Neuberg D,Phillips K,Reynolds H,Silverstein J,Clark JC,Ash M,Thompson C,Fisher DC,Jacobsen E,LaCasce AS,Freedman AS. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. British Journal of Haematology 2008; 143:361-8. PubMed
  • Brown JR, Levine RL, Thompson C, Basile G, Gilliland DG, Freedman AS. Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia 2008; 22:1966-9. PubMed
  • Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma 2008; 49:902-9. PubMed
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418-25. PubMed
  • Lacasce AS, Freedman AS. Antibody and Immunomodulatory Agents in the Treatment of Indolent Non-Hodgkin's Lymphoma. Semin Hematol 2008; 45:85-9. PubMed
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13:1057-65. PubMed
  • Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS. Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up. J Clin Oncol 2007; 25:2554-9. PubMed
  • Friedberg JW, Freedman AS. Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. Curr Treat Options Oncol 2006; 7:276-84. PubMed
  • Zubair AC, Kao G, Daley H, Schott D, Freedman A, Ritz J. CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy 2006; 8:399-407. PubMed
  • Freedman AS. Non-transplant-related treatment options in follicular lymphoma. Biol Blood Marrow Transplant 2006; 12:53-8. PubMed
  • Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106:4389-96. PubMed
  • Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:2208-14. PubMed
  • Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2004; 105:489-95. PubMed
  • Jacobsen E, Freedman A. B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol 2004; 5:711-7. PubMed
  • Munoz O, Fend F, de Beaumont R, Husson H, Astier A, Freedman AS. TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia 2004; 18:2015-25. PubMed
  • Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004; 6:33-43. PubMed
  • Brown JR, Weng AP, Freedman AS. Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. Am J Clin Pathol 2004; 121:701-8. PubMed
  • Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A, Antin JH, Soiffer RJ, Neuberg D, Ritz J. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 2004; 44:253-61. PubMed
  • Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG, Fisher DC, Freedman AS, Takvorian T, Jurgens R, Battle TE, Frank DA. Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leuk Res 2003; 28:139-47. PubMed
  • Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma 2004; 45:315-20. PubMed
  • Friedberg JW, Kim H, Li S, Neuberg D, Boyd K, Daley H, Fisher DC, Gribben JG, Spitzer T, Freedman AS. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32:681-6. PubMed
  • Lestou VS, Gascoyne RD, Sehn L, Ludkovski O, Chhanabhai M, Klasa RJ, Husson H, Freedman AS, Connors JM, Horsman DE. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol 2003; 122:745-59. PubMed
  • Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J. Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion 2003; 43:614-21. PubMed
  • Astier AL, Xu R, Svoboda M, Hinds E, Munoz O, de Beaumont R, Crean CD, Gabig T, Freedman AS. Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival. Blood 2002; 101:1118-27. PubMed
  • Husson H, Freedman AS, Cardoso AA, Schultze J, Munoz O, Strola G, Kutok J, Carideo EG, De Beaumont R, Caligaris-Cappio F, Ghia P. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol 2002; 119:492-5. PubMed
  • Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002; 117:828-34. PubMed
  • Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A 2002; 99:5367-72. PubMed
  • Husson H, Carideo EG, Neuberg D, Schultze J, Munoz O, Marks PW, Donovan JW, Chillemi AC, O'Connell P, Freedman AS. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002; 99:282-9. PubMed
  • Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002; 8:601-7. PubMed
  • Webb IJ, Friedberg W, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H, Houde H, Monroy R, Schmittling R, Freedman AS. Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2002; 8:429-34. PubMed
  • Alyea E, Neuberg D, Mauch P, Marcus K, Freedman A, Webb I, Anderson K, Schlossman R, Fisher D, Gribben J, Ritz J, Soiffer R. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002; 8:139-44. PubMed
  • Gaudet G, Friedberg JW, Weng A, Pinkus GS, Freedman AS. Breast lymphoma associated with breast implants: two case-reports and a review of the literature. Leuk Lymphoma 2002; 43:115-9. PubMed
  • Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, de Leval L, Schultze J, Freedman AS. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol 2001; 115:554-62. PubMed
  • Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 2001; 19:1152-9. PubMed
  • Friedberg JW, Neuberg D, Monson E, Jallow H, Nadler LM, Freedman AS. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2001; 7:446-53. PubMed
  • Robinson SN, Freedman AS, Neuberg DS, Nadler LM, Mauch PM. Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment. Exp Hematol 2001; 28:1325-33. PubMed
  • Husson H, Lugli SM, Ghia P, Cardoso A, Roth A, Brohmi K, Carideo EG, Choi YS, Browning J, Freedman AS. Functional effects of TNF and lymphotoxin alpha1beta2 on FDC-like cells. Cell Immunol 2000; 203:134-43. PubMed
  • Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94:3325-33. PubMed
  • Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3128-35. PubMed
  • Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5:2392-8. PubMed
  • Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC, Schlossman R, Jallow H, Kuhlman C, Ritz J, Freedman AS. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999; 5:262-8. PubMed
  • Mach-Pascual S, Legare RD, Lu D, Kroon M, Neuberg D, Tantravahi R, Stone RM, Freedman AS, Nadler LM, Gribben JG, Gilliland DG. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood 1998; 91:4496-503. PubMed
  • Soiffer RJ, Freedman AS, Neuberg D, Fisher DC, Alyea EP, Gribben J, Schlossman RL, Bartlett-Pandite L, Kuhlman C, Murray C, Freeman A, Mauch P, Anderson KC, Nadler LM, Ritz J. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21:1177-81. PubMed
  • Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson KC, Andersen N, Schlossman R, Kroon M, Ritz J, Aster J, Nadler LM. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16:13-8. PubMed
  • Ghia P, Boussiotis VA, Schultze JL, Cardoso AA, Dorfman DM, Gribben JG, Freedman AS, Nadler LM. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998; 91:244-51. PubMed
  • Astier A, Mani. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma 1998; 28:65-72. PubMed
  • Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JG. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90:4212-21. PubMed
  • Astier A, Mani. The related adhesion focal tyrosine kinase differentially phosphorylates p130Cas and the Cas-like protein, p105HEF1. J Biol Chem 1997; 272:19719-24. PubMed
  • Mani. Regulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells. A role for p59(Fyn) and SHP2. J Biol Chem 1997; 272:15636-41. PubMed
  • Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997; 89:3039-47. PubMed
  • Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant 1997; 3:11-7. PubMed
  • Astier A, Avraham H, Manie SN, Groopman J, Canty T, Avraham S, Freedman AS. The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after beta1-integrin stimulation in B cells and binds to p130cas. J Biol Chem 1997; 272:228-32. PubMed
  • Mani. Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol 1997; 25:45-50. PubMed
  • Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88:2780-6. PubMed
  • Manie SN, Astier A, Wang D, Phifer JS, Chen J, Lazarovits AI, Morimoto C, Freedman AS. Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells. Blood 1996; 87:1855-61. PubMed
  • Huang MJ, Osborn L, Svahn J, Schiffer SB, Eliseo L, Zhou LJ, Rhynhart K, Benjamin CD, Freedman AS. Expression of vascular cell adhesion molecule-1 by follicular dendritic cells. Leuk Lymphoma 1995; 18:259-64. PubMed
  • Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:2535-42. PubMed
  • Freedman AS, Saporito L, Rhynhart K, Morimoto C, Nadler LM. Adhesion of follicular lymphoma cells to lymphoid germinal centers--a potential mechanism of tumor cell homing following autologous transplantation. Leuk Lymphoma 1994; 13:47-52. PubMed
  • Freedman AS, Rhynhart K, Nojima Y, Svahn J, Eliseo L, Benjamin CD, Morimoto C, Vivier E. Stimulation of protein tyrosine phosphorylation in human B cells after ligation of the beta 1 integrin VLA-4. J Immunol 1993; 150:1645-52. PubMed
  • Freedman AS, Munro JM, Rhynhart K, Schow P, Daley J, Lee N, Svahn J, Eliseo L, Nadler LM. Follicular dendritic cells inhibit human B-lymphocyte proliferation. Blood 1992; 80:1284-8. PubMed
  • Freedman AS, Munro JM, Morimoto C, McIntyre BW, Rhynhart K, Lee N, Nadler LM. Follicular non-Hodgkin's lymphoma cell adhesion to normal germinal centers and neoplastic follicles involves very late antigen-4 and vascular cell adhesion molecule-1. Blood 1992; 79:206-12. PubMed
  • Freedman AS, Munro JM, Rice GE, Bevilacqua MP, Morimoto C, McIntyre BW, Rhynhart K, Pober JS, Nadler LM. Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science 1990; 249:1030-3. PubMed
  • Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM. B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol 1987; 139:3260-7. PubMed
Hide